OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press3610.17650/1818-8346-2013-8-2-70-76PHARMACOTHERAPYФАРМАКОТЕРАПИЯInfluence of low molecular weight heparin on cancer patients’ survivalВлияние низкомолекулярных гепаринов на выживаемость онкологических больныхPtushkinV. V.ПтушкинВ. В.
Russian Federation
vadimvadim@inbox.ruDmitry Rogachev Federal Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of RussiaФГБУ ФНКЦ ДГОИ им. Дмитрия Рогачева Минздрава России2205201382707622072014220720142013https://oncohematology.abvpress.ru/ongm/article/view/36

There is an evidence of interaction between the hemostasis system and tumor progression factors. It is known that in addition to the fibrin formation and platelets activation, thrombin can influence many cells function interacting with protease-activating receptors including tumor cells. These receptors are involved in the malignant cell phenotype formation (adhesion, proliferation, proteolysis). Thrombin can also affect angiogenesis by stimulating endothelial cells penetration through basal membrane and its migration with new vessels formation. Furthermore, it can cause the release of main neoangiogenesis promoter – vascular endothelial growth factor. All of the above and many other linkages of coagulation and tumor create a theoretical background of possible affecting tumor by regulation of the coagulation activity. Thepromise of this approach is controversial, but there is some clinical and experimental evidence of their effectiveness. The most used group ofdrugs for this purpose was heparins. Several retrospective studies have shown a benefit of low molecular weight heparins (LMWH) over unfractionated heparin in cancer patient survival. The appearance of a new heparins group – ultra LMWH are of interest from this point ofview and their possible use in cancer patients. To date bemiparin and semuloparin are used in clinic. Both (bemiparin about 3600 kDa,semuloparin 3000 kDa) have substancially reduced molecular weight as compared with the smallest of LMWH – enoxaparin (4600 kDa).Use of bemiparin in patients with small cell lung cancer receiving chemotherapy resulted in increased of 2-year survival rate compared to the control group (68.6 % vs. 29.4 %, p = 0.0042).

ultra low molecular weight heparinslow molecular weight heparinscancermetastasissurvivalультранизкомолекулярные гепаринынизкомолекулярные гепариныопухольметастазированиевыживаемость1. Trousseau A. Phlegmasia alba dolens. In: Trousseau A., ed. Clinique medicale de l’Hotel-Dieu de Paris. Baillière: Paris; 1865. Pp. 654–712.Trousseau A. Phlegmasia alba dolens. In: Trousseau A., ed. Clinique medicale de l’Hotel-Dieu de Paris. Baillière: Paris; 1865. Pp. 654–712.2. Kakkar A.K., DeRuvo H., Chinswanqtanakul V. et al. Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor. Lancet 1995;346(8981):1004–5.Kakkar A.K., DeRuvo H., Chinswanqtanakul V. et al. Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor. Lancet 1995;346(8981):1004–5.3. Kakkar A.K., Chinswangwatanakul V., Tebbutt S. et al. A characterization of the coagulant and fibrinolytic profile of human pancreatic carcinoma cells. Haemostasis 1998;28:1–6.Kakkar A.K., Chinswangwatanakul V., Tebbutt S. et al. A characterization of the coagulant and fibrinolytic profile of human pancreatic carcinoma cells. Haemostasis 1998;28:1–6.4. Luzzato G., Schafer A.L. The prethrombotic state in cancer. Semin Oncol 1990;17:147–59.Luzzato G., Schafer A.L. The prethrombotic state in cancer. Semin Oncol 1990;17:147–59.5. Francis J.L. Haemostasis and cancer. Med Lab Sci 1989;46:331–46.Francis J.L. Haemostasis and cancer. Med Lab Sci 1989;46:331–46.6. Decensi A., Maisonneuve P., Rotmensz N. et al. Effect of tamoxifen on venous tromboembolic events in a breast cancer prevention Circulation 2005;111:650–6.Decensi A., Maisonneuve P., Rotmensz N. et al. Effect of tamoxifen on venous tromboembolic events in a breast cancer prevention Circulation 2005;111:650–6.7. Sorensen H.T., Mellemkjaer L., Olsen J.H. et al. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000;343:1846–50.Sorensen H.T., Mellemkjaer L., Olsen J.H. et al. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000;343:1846–50.8. Beer J.H., Haeberli A., Vogt A. et al. Coagulation markers predict survival in cancer patients. Thromb Haemost 2002;88:745–9.Beer J.H., Haeberli A., Vogt A. et al. Coagulation markers predict survival in cancer patients. Thromb Haemost 2002;88:745–9.9. Miller G.J., Bauer K.A., Howarth D.J. et al. Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway. J Thromb Haemost 2004;2:2107–14.Miller G.J., Bauer K.A., Howarth D.J. et al. Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway. J Thromb Haemost 2004;2:2107–14.10. Green D., Hull R.D., Brant R., Pineo G.F. Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin. Lancet 1992;339:1476.Green D., Hull R.D., Brant R., Pineo G.F. Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin. Lancet 1992;339:1476.11. Ginsberg J.S. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med 1996;100:269–77.Ginsberg J.S. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med 1996;100:269–77.12. Zacharski L.R., Ornstein D.L., Mamourian A.C. Low-molecular-weight heparin and cancer. Semin Thromb Hemost 2000;26 Suppl 1:69–77.Zacharski L.R., Ornstein D.L., Mamourian A.C. Low-molecular-weight heparin and cancer. Semin Thromb Hemost 2000;26 Suppl 1:69–77.13. Bobek V., Kovarik J. Antitumor and antimetastatic effect of warfarin and heparins. Biomed Pharmacother 2004;58:213–9.Bobek V., Kovarik J. Antitumor and antimetastatic effect of warfarin and heparins. Biomed Pharmacother 2004;58:213–9.14. Wang A., Templeton D.M. Inhibition of mitogenesis and c-fos induction in mesangial cells by heparin and heparan sulfates. Kidney Int 1996;49(2):437–48.Wang A., Templeton D.M. Inhibition of mitogenesis and c-fos induction in mesangial cells by heparin and heparan sulfates. Kidney Int 1996;49(2):437–48.15. Folkman J., Weisz P.B., Joullie M.M. et al. Control of angiogenesis with synthetic heparin substitutes. Science 1989;243: 1490–3.Folkman J., Weisz P.B., Joullie M.M. et al. Control of angiogenesis with synthetic heparin substitutes. Science 1989;243: 1490–3.16. Collen A., Koolwijk P., Kroon M.E., van Hinsbergh V.W.M. The influence of fibrin structure on the formation and maintenance of capillary-like tubules.Angiogenesis 1998;2:153–165.Collen A., Koolwijk P., Kroon M.E., van Hinsbergh V.W.M. The influence of fibrin structure on the formation and maintenance of capillary-like tubules.Angiogenesis 1998;2:153–165.17. Mousa S.A., Mohamed S. Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor. Thromb Haemost 2004;92:627–3.Mousa S.A., Mohamed S. Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor. Thromb Haemost 2004;92:627–3.18. Wahrenbrock M., Borsig L., Le D. et al. Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas J Clin Invest 2003;112(6):853–62.Wahrenbrock M., Borsig L., Le D. et al. Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas J Clin Invest 2003;112(6):853–62.19. Biggerstaff J.P., Seth N., Amirkhosravi A. et al. Soluble fibrin augments platelet/tumor cell adherence in vitro and in vivo and enhances experimental metastasis. Clin Exp Metastasis 1999;17:723–90.Biggerstaff J.P., Seth N., Amirkhosravi A. et al. Soluble fibrin augments platelet/tumor cell adherence in vitro and in vivo and enhances experimental metastasis. Clin Exp Metastasis 1999;17:723–90.20. Clifton E.E., Agostino D. Factors affecting the development of metastatic cancer. Cancer 1962;15:276–83.Clifton E.E., Agostino D. Factors affecting the development of metastatic cancer. Cancer 1962;15:276–83.21. Lee A.E., Rogers L.A., Jeffery R.E., Longcroft J.M. Comparison of metastatic cell lines derived from a murine mammary tumor, and reduction of metastasis by heparin. Clin Exp Metastasis 1988;6:463–71.Lee A.E., Rogers L.A., Jeffery R.E., Longcroft J.M. Comparison of metastatic cell lines derived from a murine mammary tumor, and reduction of metastasis by heparin. Clin Exp Metastasis 1988;6:463–71.22. Angelini A., Di Febbo C., Ciofani G. et al. Inhibition of P-Glycoprotein-mediated multidrug resistance by unfractionated heparin: a new potential chemosensitizer for cancer therapy. Cancer Biol Ther 2005;4:313–7.Angelini A., Di Febbo C., Ciofani G. et al. Inhibition of P-Glycoprotein-mediated multidrug resistance by unfractionated heparin: a new potential chemosensitizer for cancer therapy. Cancer Biol Ther 2005;4:313–7.23. Ghosh B.C., Cliffton E.E. Malignant tumors with superior vena cava obstruction. NY State J Med 1973;73:283–9.Ghosh B.C., Cliffton E.E. Malignant tumors with superior vena cava obstruction. NY State J Med 1973;73:283–9.24. Lebeau B., Chastang C.L., Brechot J.M. Subcutaneous heparin treatment increases complete response rate and overall survival in small cell lung cancer. Lung Cancer 1991;7(Suppl):129–34.Lebeau B., Chastang C.L., Brechot J.M. Subcutaneous heparin treatment increases complete response rate and overall survival in small cell lung cancer. Lung Cancer 1991;7(Suppl):129–34.25. Hirsh J., Warkentin T.E., Shaughnessy S.G. et al. Heparin and low-molecular-weight heparin mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001Jan;119(1 Suppl):64S–94S.Hirsh J., Warkentin T.E., Shaughnessy S.G. et al. Heparin and low-molecular-weight heparin mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001Jan;119(1 Suppl):64S–94S.26. Prandoni P., Lensing A.W., Buller H.R. et al. Comparison of subcutaneous low-molecular- weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 992;339(8791):441–5.Prandoni P., Lensing A.W., Buller H.R. et al. Comparison of subcutaneous low-molecular- weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 992;339(8791):441–5.27. Hettiarachchi R.J., Smorenburg S.M. Ginsberg J. Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb Haemost 1999;82(2):947–52.Hettiarachchi R.J., Smorenburg S.M. Ginsberg J. Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb Haemost 1999;82(2):947–52.28. Gould M., Dembitzer A.D., Doyle R.L. et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 1999;130:800–9.Gould M., Dembitzer A.D., Doyle R.L. et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 1999;130:800–9.29. Khorana A.A., Sahni A., Altland O.B., Francis C.W. Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight arteriosclerosis, thrombosis, and vascular biology. Arterioscler Thromb Vasc Biol 2003;23:2110–5.Khorana A.A., Sahni A., Altland O.B., Francis C.W. Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight arteriosclerosis, thrombosis, and vascular biology. Arterioscler Thromb Vasc Biol 2003;23:2110–5.30. Collen A., Smorenburg M., Peters E. Unfractionated and low molecular weight heparin affect fibrin structure and angiogenesis in vitro. Cancer Res 2000;60:6196–200.Collen A., Smorenburg M., Peters E. Unfractionated and low molecular weight heparin affect fibrin structure and angiogenesis in vitro. Cancer Res 2000;60:6196–200.31. Castelli R., Porro F., Tarsia P. The heparins and cancer: review of clinical trials and biological properties. Vasc Med 2004 May;9(3):205–13.Castelli R., Porro F., Tarsia P. The heparins and cancer: review of clinical trials and biological properties. Vasc Med 2004 May;9(3):205–13.32. Planès A. Review of bemiparin sodium – a new second-generation low molecular weight heparin and its applications in venous thromboembolism. Expert Opin Pharmacother 2003;4(9):1551–61.Planès A. Review of bemiparin sodium – a new second-generation low molecular weight heparin and its applications in venous thromboembolism. Expert Opin Pharmacother 2003;4(9):1551–61.33. Gomez-Outes A., Suarez-Gea M.L., Lecumberri R. et al. New parenteral anticoagulants in development. Ther Adv Cardiovasc Dis 2010;5(1):33–59.Gomez-Outes A., Suarez-Gea M.L., Lecumberri R. et al. New parenteral anticoagulants in development. Ther Adv Cardiovasc Dis 2010;5(1):33–59.34. Broze G.J., Warren L.A., Novotny W.F. et al. The lipoprotein-associated coagulationinhibitor that inhibits the factor VIIa-tissue factor complex, also inhibits factor Xa: insight into its possible mechanism of action. Blood 1988;71:335–43.Broze G.J., Warren L.A., Novotny W.F. et al. The lipoprotein-associated coagulationinhibitor that inhibits the factor VIIa-tissue factor complex, also inhibits factor Xa: insight into its possible mechanism of action. Blood 1988;71:335–43.35. Mueller B.M., Reisfeld R.A., Edgington T.S., Ruf W. Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci USA 1992;89:11832–36.Mueller B.M., Reisfeld R.A., Edgington T.S., Ruf W. Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci USA 1992;89:11832–36.36. Im J.H., Fu W., Wang H. et al. Coagulation facilitates tumor cell spreading in the pulmonary vasculature during early metastatic colony formation. Cancer Res 2004;64:8613–9.Im J.H., Fu W., Wang H. et al. Coagulation facilitates tumor cell spreading in the pulmonary vasculature during early metastatic colony formation. Cancer Res 2004;64:8613–9.37. Palumbo J.S., Talmage K.E., Massari J.V. et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 2005;105:178–85.Palumbo J.S., Talmage K.E., Massari J.V. et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 2005;105:178–85.38. Amirkhosravi A., Mousa S.A., Amaya M. et al. Assessment of anti-metastatic effects of anticoagulant and antiplatelet agents using animal models of experimental lung metastasis. Methods Mol Biol 2010;663:241–59.Amirkhosravi A., Mousa S.A., Amaya M. et al. Assessment of anti-metastatic effects of anticoagulant and antiplatelet agents using animal models of experimental lung metastasis. Methods Mol Biol 2010;663:241–59.39. Westmuckett A.D., Kakkar V.V., Hamuro T. et al. Bemiparin and fluid flow modulate the expression, activity and release of tissue factor pathway inhibitor in human endothelial cells in vitro. Thromb Haemost 2001 Dec;86(6):1547–54.Westmuckett A.D., Kakkar V.V., Hamuro T. et al. Bemiparin and fluid flow modulate the expression, activity and release of tissue factor pathway inhibitor in human endothelial cells in vitro. Thromb Haemost 2001 Dec;86(6):1547–54.40. Falkon L., Garí M., Barbanoj M. et al. Tissue factor pathway inhibitor and anti-FXa kinetic profiles of a new low-molecular-mass heparin, bemiparin, at therapeutic subcutaneous doses. Blood Coagul Fibrinolysis 1998 Mar;9(2):137–41.Falkon L., Garí M., Barbanoj M. et al. Tissue factor pathway inhibitor and anti-FXa kinetic profiles of a new low-molecular-mass heparin, bemiparin, at therapeutic subcutaneous doses. Blood Coagul Fibrinolysis 1998 Mar;9(2):137–41.41. Pérez-Ruiz A., Montes R., Carrasco P., Rocha E. Effects of a low molecular weight heparin, bemiparin, and unfractionated heparin on hemostatic properties of endothelium. Clin Appl Thromb Hemost 2002 Jan;8(1):65–71. 42. Vignoli A., Marchetti M., Russo L. et al. LMWH bemiparin and ULMWH RO-14 reduce the endothelial angiogenic features elicited by leukemia, lung cancer, or breast cancer cells. Cancer Invest 2011 Feb;29(2):153–6.Pérez-Ruiz A., Montes R., Carrasco P., Rocha E. Effects of a low molecular weight heparin, bemiparin, and unfractionated heparin on hemostatic properties of endothelium. Clin Appl Thromb Hemost 2002 Jan;8(1):65–71. 42. Vignoli A., Marchetti M., Russo L. et al. LMWH bemiparin and ULMWH RO-14 reduce the endothelial angiogenic features elicited by leukemia, lung cancer, or breast cancer cells. Cancer Invest 2011 Feb;29(2):153–6.43. Kakkar A.K., Levine M.N., Kadziola Z. et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the Fragmin Advanced Malignancy Outcome Study (FAMOUS). J Clin Oncol 2004;22:1944–8.Kakkar A.K., Levine M.N., Kadziola Z. et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the Fragmin Advanced Malignancy Outcome Study (FAMOUS). J Clin Oncol 2004;22:1944–8.44. Klerk C.P.W., Smorenburg S.M., Otten H.M. et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005;23:2130–5.Klerk C.P.W., Smorenburg S.M., Otten H.M. et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005;23:2130–5.45. van Doormaal F.F., Di Nisio M., Otten H.M. et al. Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. J Clin Oncol 2011;29:2071–6.van Doormaal F.F., Di Nisio M., Otten H.M. et al. Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. J Clin Oncol 2011;29:2071–6.46. Massuti B., Lecumberri R., Lopez Vivanco G.M. et al., ABEL trial. A phase II randomized trial adding bemiparin (B) to chemo-radiotherapy (CT-RT) in limited-stage small cell lung cancer (SCLC). Final results. J Clin Oncol 30, 2012 (suppl; abstr. 7095).Massuti B., Lecumberri R., Lopez Vivanco G.M. et al., ABEL trial. A phase II randomized trial adding bemiparin (B) to chemo-radiotherapy (CT-RT) in limited-stage small cell lung cancer (SCLC). Final results. J Clin Oncol 30, 2012 (suppl; abstr. 7095).47. Agnelli G., George D.J., Kakkar A.K. et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 2012;366:601–9.Agnelli G., George D.J., Kakkar A.K. et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 2012;366:601–9.48. Akl E.A., Schünemann H.J. Routine heparin for patients with cancer? One answer, more questions. N Engl J Med 2012 Feb 16;366(7):661–2.Akl E.A., Schünemann H.J. Routine heparin for patients with cancer? One answer, more questions. N Engl J Med 2012 Feb 16;366(7):661–2.49. Akl E.A., Gunukula S., Barba M. et al. Parenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. Cochrane Database Syst Rev 011;4:CD006652.Akl E.A., Gunukula S., Barba M. et al. Parenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. Cochrane Database Syst Rev 011;4:CD006652.